Pure Bioscience Reports Director Changes and Compensation
Ticker: PURE · Form: 8-K · Filed: Nov 19, 2025 · CIK: 1006028
| Field | Detail |
|---|---|
| Company | Pure Bioscience, Inc. (PURE) |
| Form Type | 8-K |
| Filed Date | Nov 19, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: director-change, executive-compensation, corporate-governance
TL;DR
Pure Bioscience shakes up the board and adjusts exec pay.
AI Summary
Pure Bioscience, Inc. filed an 8-K on November 19, 2025, reporting on the departure of directors, election of new directors, and compensatory arrangements. The filing covers events that occurred on November 17, 2025, and includes information related to financial statements and exhibits.
Why It Matters
Changes in a company's board of directors and executive compensation can signal shifts in strategy or governance, impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may affect the company's future direction and stability.
Key Players & Entities
- PURE BIOSCIENCE, INC. (company) — Registrant
- November 17, 2025 (date) — Earliest event reported
- November 19, 2025 (date) — Filing date
FAQ
What specific director positions were affected by the departures and elections?
The filing indicates the departure of directors and the election of new directors, but does not specify the exact positions or names of the individuals involved in this excerpt.
Were there any specific compensatory arrangements disclosed for the officers?
The filing mentions 'Compensatory Arrangements of Certain Officers' as an item of disclosure, but the details of these arrangements are not provided in this excerpt.
What is the significance of the 'Financial Statements and Exhibits' being included?
The inclusion of 'Financial Statements and Exhibits' suggests that the company is providing updated financial information or related documents alongside the reported corporate governance changes.
What is the company's primary business according to its SIC code?
Pure Bioscience, Inc. is classified under SIC code 2890, which corresponds to Miscellaneous Chemical Products.
When was the company incorporated and where is its principal executive office?
The company is incorporated in Delaware and its business address is 771 Jamacha Road #512, El Cajon, CA 92019.
Filing Stats: 686 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2025-11-19 16:30:53
Filing Documents
- form8-k.htm (8-K) — 34KB
- ex99-1.htm (EX-99.1) — 9KB
- 0001493152-25-024276.txt ( ) — 202KB
- pure-20251117.xsd (EX-101.SCH) — 3KB
- pure-20251117_lab.xml (EX-101.LAB) — 33KB
- pure-20251117_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PURE BIOSCIENCE, INC. Dated: November 19, 2025 By: /s/ Robert F. Bartlett Robert F. Bartlett Chief Executive Officer